Amgen partnering to develop new drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Teledyne subsidiary acquires Scientific Systems
Teledyne Instruments, an arm of Thousand Oaks-based aerospace and defense company Teledyne Technologies, announced that it would acquire Pennsylvania piston pump maker Scientific Systems, Inc. Teledyne is one of SSI’s larger customers, Teledyne President and CEO Robert Mehrabian said in a news release. “SSI will provide Teledyne greater access to life sciences customers and markets, Read More →
Read More →Conejo Valley biotech scene heats up with Sienna IPO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen’s Kyprolis found to increase cancer survival rate
A Phase 3 clinical study of Amgen’s multiple myeloma drug Kyprolis showed that it increased overall survival rate when paired with lenalidomide and dexamethasone versus just those two drugs alone. The drug reduced the risk of death by 21 percent, and patients lived 7.9 months longer when on a regimen that included Kyprolis than those Read More →
Read More →FDA gives full approval to Amgen leukemia drug Blincyto
Amgen’s leukemia drug Blincyto received full approval from the U.S. Food and Drug Administration on July 11 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children. The biotech giant, headquartered in Thousand Oaks, had previously announced that the drug had been fast-tracked for priority review. The full approval includes data Read More →
Read More →Amgen asks FDA to consider new uses for Xgeva
Thousand Oaks-based biotech giant Amgen announced June 19 that the U.S. Food and Drug Administration has accepted a supplemental application for Xgeva (denosumab) that seeks to expand the currently approved indication for the prevention of fractures and other skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. “Multiple Read More →
Read More →Ernst & Young gives entrepreneur awards to Direct Relief, TrackR
Ernst & Young honored two members of the Santa Barbara business community at its annual Entrepreneur of the Year awards for the Greater Los Angeles Region on June 15. Thomas Tighe, president and CEO of Direct Relief, received the Social Entrepreneurship recognition. Also among the eight winners was tracking device company TrackR, co-founded by Chris Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
